<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00163267</url>
  </required_header>
  <id_info>
    <org_study_id>mi-1</org_study_id>
    <secondary_id>D.3100340</secondary_id>
    <nct_id>NCT00163267</nct_id>
  </id_info>
  <brief_title>Mirror Trial - Follow-Up Management of Peripheral Arterial Intervention With Clopidogrel</brief_title>
  <official_title>Follow-up Management of Peripheral Arterial Intervention With Clopidogrel MIRROR-Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <brief_summary>
    <textblock>
      The Mirror Study is a randomized, double-blinded mono-centre trial the access the
      periinterventinal and postinterventional administration of clopidogrel in patients with
      peripheral vascular disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clopidogrel is approved for secondary prevention of atherosclerosis in patients with
      peripheral vascular disease. Currently there are no data about the amount of platelet
      activation during peripheral arterial intervention, the effect of clopidogrel on platelet
      adhesion and its clinical impact.

      Patients with chronic peripheral arterial disease receive placebo or clopidogrel before the
      intervention and for 6 months in follow-up. Platelet activation, the effect on macro-and
      microcirculation will be assessed as well as clinical endpoints.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet activation during and after the intervention</measure>
    <time_frame>6-12 hours</time_frame>
    <description>measured in a chandler loop model</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ABI</measure>
    <time_frame>before patients leaves the hospital and at 6 months</time_frame>
    <description>as treatment effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinical improvement</measure>
    <time_frame>up to 6 months</time_frame>
    <description>dependent on the additional drug treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>up to 6 months</time_frame>
    <description>dependent on the drug treatment with the endovascular treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of occlusions</measure>
    <time_frame>wihtin 6 months</time_frame>
    <description>dependent on drug treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Peripheral Vascular Diseases</condition>
  <arm_group>
    <arm_group_label>ASS + Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>control arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASS + Plavix</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>active drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clopidogrel</intervention_name>
    <description>Best endovascular treatment either with one or the other drug arm should be investigated</description>
    <arm_group_label>ASS + Placebo</arm_group_label>
    <arm_group_label>ASS + Plavix</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Peripheral arterial disease which requires intervention

        Exclusion Criteria:

          -  Patient already on coumadin or clopidogrel

          -  Acute onset of PVD symptoms

          -  Patient requiring an operation

          -  Contraindication to aspirin and clopidogrel
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gunnar Tepe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Tuebingen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2005</study_first_posted>
  <last_update_submitted>August 5, 2011</last_update_submitted>
  <last_update_submitted_qc>August 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 9, 2011</last_update_posted>
  <responsible_party>
    <name_title>Mirror Trial</name_title>
    <organization>University of Tuebingen</organization>
  </responsible_party>
  <keyword>peripheral arterial intervention</keyword>
  <keyword>atherosclerosis</keyword>
  <keyword>platelets</keyword>
  <keyword>Age above 18</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

